

# **Novel Mango Ginger Bioactive (2,4,6-trihydroxy-3,5-diprenyldihydrochalcone) Inhibits Mitochondrial Metabolism in Combination with Avocatin B**

Varsha Jayasankar<sup>1</sup>, Nikolina Vrdoljak<sup>1</sup>, Alessia Roma<sup>1</sup>, Nawaz Ahmed<sup>1</sup>, Matthew Tcheng<sup>1</sup>, Mark D. Minden<sup>2</sup>, and Paul A. Spagnuolo<sup>1\*</sup>

<sup>1</sup> Department of Food Science, University of Guelph, 50 Stone Rd. Guelph Ontario, Canada. N1G2W1

<sup>2</sup> University Health Network, 610 University Ave, Toronto, ON, CAN M5G 2C4

\* Correspondence:

Paul A. Spagnuolo, Ph.D.  
Associate Professor, Department of Food Science  
University of Guelph  
Guelph, Ontario, N1G 2W1  
Phone: (519) 824-4120 x53732  
paul.spagnuolo@uoguelph.ca

# Supplementary Information

## Part 1: Methods

### Avocatin B Extraction

Hass avocado seeds were air dried, crushed and placed in glass bottles with ethyl acetate in a 2:1 solvent: seed ratio. The bottles were sealed and rotated on a 120 Vac Benchtop Roller (Wheaton; Millville, NJ) for 24 hours. Extracts were then gravity filtered and the solvent was evaporated using a Rotavapor® R-100 rotary evaporator (BÜCHI Labortechnik AG, Flawil, Switzerland) twice. The crude extract was purified using flash chromatography using a silica (Fisher Scientific; Mississauga, ON) column and ethyl acetate as the mobile phase. Column fractions were analyzed for purity using thin layer chromatography (eluent: ethyl acetate,  $R_f = 0.30$ ) and visualized using p-anisaldehyde stain (Fisher). All purified samples were characterized by  $^1\text{H}$  NMR. Samples were dissolved to 2 mg/mL in deuterated chloroform ( $\text{CDCl}_3$ ) and transferred to an NMR tube. The samples were then analyzed using an Avance 400 MHz

spectrometer (Bruker; Billerica, Massachusetts) and recorded as parts per million (ppm).

Purified Avo B was dissolved in DMSO for experimental use.

### **Combination Index Calculations**

CI values were calculated using the Chou-Talalay Combination Index Method, using the following formula based on the median-effect equation

$$CI = \frac{(D)_1}{(D_x)_1} + \frac{(D)_2}{(D_x)_2}$$

where  $(Dx)_1$  is a concentration of the first drug individually that inhibits a system by  $x\%$ , and  $(Dx)_2$  is a concentration of the second drug individually that inhibits a system by the same  $x\%$ . The numerator,  $(D)_1$  and  $(D)_2$ , are the drug concentrations in the combination that also inhibit  $x\%$ .

### **Respirometry**

#### **Cell Culture**

Cell viability was determined using trypan blue 0.4% cell stain (Gibco) and counting using a hemocytometer. Cells with  $\geq 95\%$  viability were used for cell culture. OCI-AML2 and OCI-AML3 cells were cultured in 100 mm cell culture dishes (Corning) at a density

of  $0.5 \times 10^6$  cells/mL in 10mL of IMDM media; 10 million cells were required for each treatment. The desired treatment (1 $\mu$ M M1, 2 $\mu$ M Avo B, 1 $\mu$ M M1 + 2 $\mu$ M Avo B, or DMSO) was added and the plates were incubated in 5% CO<sub>2</sub> at 37°C for 1 hour.

### **Permeabilization**

After incubation, the cells required for 1 treatment were collected and centrifuged at 1200 rpm for 5 minutes. The media was then removed, and the pellet was resuspended in 1mL of PBS. The pellet was then transferred to a 1.5mL microcentrifuge tube and centrifuged at 1200 rpm for 5 minutes in a microcentrifuge. Following the second centrifugation, the PBS wash was carefully removed, and the pellet was suspended in 500  $\mu$ L permeabilization buffer (80mM KCl and 250mM sucrose in PBS) containing 0.01% digitonin (Sigma-Aldrich). The mixture was then agitated gently for 3 minutes, centrifuged at 1200 rpm for 5 minutes, and recentrifuged for one more cycle after the permeabilization buffer was removed. The pellet was then suspended in 150 $\mu$ L of MiR05 respiration buffer and injected into the Oroboros Oxygraph-2k (Oroboros Instruments; Innsbruck, Austria) chambers. The Oroboros Oxygraph-2k chambers

contained 2mL of MiR05 mitochondrial respiration medium (0.5mM EGTA, 3mM MgCl<sub>2</sub>, 60mM lactobionic acid, 20mM taurine, 10mM KH<sub>2</sub>PO<sub>4</sub>, 20mM HEPES, 110mM D-sucrose, 1 mg/mL bovine serum albumin (BSA) in ddH<sub>2</sub>O) [93]. Basal respiration was measured after injection, once steady-state respiratory flux was obtained.

## **Electron Transport Chain Activity**

### **Mitochondria Rich Fraction Preparation**

Using AML2 cells, 15x10<sup>6</sup> cells were collected and centrifuged for 5 minutes at 1200 rpm. The cells were washed with 1mL PBS for 5 minutes at 1200 rpm; the supernatant was discarded, and the pellet was retained. The pellet was then flash frozen in liquid nitrogen, thawed on ice, and resuspended in 10mM of ice-cold hypotonic Tris HCl buffer. The cells were homogenized with 3 pulses on Fisherbrand Model 120 Sonic Dismembrator (Fisher Scientific), with each pulse consisting of 3 seconds on, 3 seconds off at 45% amplitude. The cell homogenate was mixed thoroughly with 200µL of a 1.5M sucrose solution and centrifuged at 600g for 10 minutes at 2°C using a microcentrifuge. The supernatant was then collected in a 1.5mL microcentrifuge tube

and centrifuged at 14000g for 10minutes at 2°C. The supernatant was discarded, and the pellet was resuspended in 150µL of 10mM ice-cold hypotonic Tris HCl buffer and divided into aliquots for protein estimation.

### **BCA Assay**

The total protein content of the mitochondria fraction was quantified using the BCA protein assay. BSA standards at 0, 20, 40, 60, 80, and 100 µg/mL were created and 10µL of each standard was plated in triplicate in a 96-well plate. The mitochondrial rich fraction was diluted 10x using ddH<sub>2</sub>O, and 10µL of this dilution was added to the 96-well plate in triplicate. Bicinchoninic acid (BCA) working reagent was then prepared containing 50 parts BCA (Sigma-Aldrich) to one-part 4% copper II sulphate (Sigma-Aldrich). The BCA working reagent was added to each BSA standard and sample well in the 96-well plate. The optical density was measured at 527nm using the Synergy HT spectrophotometer. Protein content of the sample was estimated using the standard curve.

## Supplementary Figure 1




Figure S1: M1 interactions with Avo B in U937 and TEX cells. Equal molar concentrations of M1 and Avo B were incubated with U937 (left) or TEX (right) leukemia cells and cell viability was measured after 72 h by flow cytometry using 7AAD. Combination index (CI) values, which assesses drug-interaction effects, were calculated using the CompuSyn software. CI values of <1, >1 or equal to 1 denote statistical synergy, antagonism, or additivity, respectively. All experiments are n=3, data is mean  $\pm$  SD. Representative figures shown.